The future of cell culture-based influenza vaccine production

Expert Review of Vaccines

Volumn 10, Issue 8, 2011, Pages 1183-1194

  Perdue, Michael L ^a   Arnold, Frank ^a   Li, Sheng ^a   Donabedian, Armen ^a   Cioce, Vittoria ^a   Warf, Thomas ^a   Huebner, Robert ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

cell lines for vaccines; cell based vaccine manufacture; influenza vaccines; recombinant influenza vaccines

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPLOID CELL VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MUMPS VACCINE; POLIOMYELITIS VACCINE; PREFLUCEL; RABIES VACCINE; RABIVAX; RECOMBINANT HEPATITIS B VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE; TICK BORNE ENCEPHALITIS VACCINE; TRESIVAC; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

CELL CULTURE; CHICKEN; CULTURE TECHNIQUE; DOWNSTREAM PROCESSING; DRUG CONTAMINATION; DRUG MARKETING; EGG; FIBROBLAST CULTURE; GOOD MANUFACTURING PRACTICE; GOVERNMENT; HUMAN; INFLUENZA VIRUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; REVIEW; SACCHAROMYCES CEREVISIAE; ULTRAFILTRATION; UNITED STATES; VACCINE PRODUCTION; VALIDATION STUDY; VIROGENESIS; WORLD HEALTH ORGANIZATION;

ANIMALS; CELL CULTURE TECHNIQUES; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 80052061981     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.82     Document Type: Review

References (101)

1. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 8(5), 607-618 (2009)
2. Bernstein DI. Cell culture-derived influenza vaccines: has their time come? Clin. Infect. Dis. 1(9), 1005-1006 (2010)
3. Eng SZ, Jiao PR, Qi WB, Fan HY, Liao M. Development and strategies of cell-culture technology for influenza vaccine. Appl. Microbiol. Biotechnol. 89(4), 893-902 (2011)
4. Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines 8(12), 1681-1692 (2009)
5. Minor PD. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin. Infect. Dis. 50, 560-564 (2010)
6. Paillet C, Forno G, Kratje R, Etcheverrigaray M. Suspension-Vero cell cultures as a platform for viral vaccine production. Vaccine 27(46), 6464-6467 (2009)
7. Petricciani J. Cell substrates: where do we stand after 50 years of discussion? Dev. Biol. (Basel) 123, 11-21; discussion 55-73 (2006) (Pubitemid 43207145)
8. Rappuoli R. Cell-culture-based vaccine production: technological options. The Bridge 36(3), 25-30 (2006)
9. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ. 73 (4), 431-435 (1995)
10. Chang L, Crichton R, Nandapalan P. Cell culture influenza vaccine: an Australian perspective. Dev. Biol. Stand. 98, 177-181; discussion 197 (1999)
11. Griffiths E. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals: application to influenza vaccine production. Dev. Biol. Stand. 98, 153-157 (1999)
12. Magrath DI. Safety of vaccines produced in continuous cell lines. Dev. Biol. Stand. 75, 17-20 (1991)
13. Merten OW, Manuguerra JC, Hannoun C, van der Werf S. Production of influenza virus in serum-free mammalian cell cultures. Dev. Biol. Stand. 98, 23-37; discussion 73-74 (1999)
14. Merten OW, Hannoun C, Manuguerra JC, Ventre F, Petres S. Production of influenza virus in cell cultures for vaccine preparation. Adv. Exp. Med. Biol. 397, 141-151 (1996) (Pubitemid 126441238)
15. Mills J, Van Kirk J, Hill DA, Chanock RM. Evaluation of influenza virus mutants for possible use in a live virus vaccine. Bull. World Health Organ. 41(3), 599-606 (1969)
16. Robertson JS, Cook P, Attwell AM, Williams SP. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue-culture derived virus: implications for vaccine manufacture. Vaccine 13(16), 1583-1588 (1995)
17. Tannock GA, Bryce DA, Paul JA. Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-ca. Vaccine 3(3), 333-339 (1985) (Pubitemid 15228985)
18. Unanov SS, Iuminova NV. Characteristics of the immunological response in children to the administration of a live tissue-culture influenza vaccine. Vopr. Virusol. 27(3), 301-305 (1982) (Pubitemid 12095709)
19. Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJ. Influvac: a safe Madin Darby canine kidney (MDCK) cell culture-based influenza vaccine. Dev. Biol. Stand. 98, 93-100 (1999)
20. Medema JK. Wijnands DT, Abraham M. Palache The role of MDCK-based influenza vaccine Influvac®TC in (inter) pandemics. Options for the Control of Influenza V. Proceedings of the International Conference on Options for the Control of Influenza V International Congress Series 1263, 822-825 (2004)
21. Blume S, Geesing I. A brief history of polio vaccines. Science 288 (5471), 1593-1594 (2000) (Pubitemid 30387415)
22. Montagnon BJ, Fanget B, Vincent-Falquet JC. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev. Infect. Dis. 6(Suppl. 2), S341-S344 (1984)
23. Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25, 3871-3878 (2007) (Pubitemid 46589748)
24. Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 37, 182-189 (2009)
25. Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3(1), e1501 (2008)
26. Haynes JR. Influenza virus-like particle vaccines. Expert Rev. Vaccines 8(4), 435-445 (2009)
27. Kang SM, Pushko P, Bright RA, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. Immunol. 333, 269-289 (2009)
28. Schultz-Cherry S, Dybing JK, Davis NL, et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278, 55-59 (2000) (Pubitemid 32002594)
29. Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23(8), 1029-1036 (2005) (Pubitemid 40037652)
30. Mayrhofer J, Coulibaly S, Hessel A, et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J. Virol. 83(10), 5192-5203 (2009)
31. Chichester JA, Haaheim LR, Yusibov V. Using plant cells as influenza vaccine substrates. Expert Rev. Vaccines 8(4), 493-498 (2009)
32. Lewis JA, Brown EL, Duncan PA. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev. Biol. (Basel) 123, 165-176; discussion 183-197 (2006) (Pubitemid 43207159)
33. Liu J. Mani S. Schwartz R, Richman L, Tabor DE. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 27(46), 6460-6463 (2009)
34. Hu AY, Weng TC, Tseng YF, et al. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccine. Vaccine 26(45), 5736-5740 (2008)
35. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16(9-10), 960-968 (1998) (Pubitemid 28276008)
36. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19, 2716-2721 (2001) (Pubitemid 32234294)
37. Matthews JT. Egg based production of influenza vaccine: 30 years of commercial experience. The Bridge 36(3), 17-24 (2006)
38. Soons ZI, van den IJssel J, van der Pol LA, van Straten G, van Boxtel AJ. Scaling-up vaccine production: implementation aspects of a biomass growth observer and controller. Bioprocess. Biosyst. Eng. 32(3), 289-299 (2009)
39. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19, 3444-3450 (2001) (Pubitemid 32710294)
40. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin. Infect. Dis. 51(9), 997-1004 (2010)
41. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 27(5), 786-791 (2009)
42. Halperin SA, Smith B, Mabrouk T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20(7-8), 1240-1247 (2002) (Pubitemid 34135962)
43. Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20-S23 (1997) (Pubitemid 27315341)
44. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis. 200(6), 849-857 (2009)
45. Smith B, Mabrouk T, Germain M, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20(7-8) 1240-1247 (2002) (Pubitemid 34135962)
46. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 200(6), 841-848 (2009)
47. Cox RJ, Madhun AS, Hauge S, et al. A Phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27, 1889-1897 (2009)
48. Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 27(43), 6022-6029 (2009)
49. Baylor NW, Houn F. Considerations for licensure of influenza vaccines with pandemic and prepandemic indications. Curr. Top. Microbiol. Immunol. 333, 453-470 (2009)
50. Gregersen JP. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 26, 3332-3340 (2008)
51. Kapteyn JC, Porre AM, de Rond EJ, et al. HPLC-based quantification of haemagglutinin in the production of egg-and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 27(9), 1468-1477 (2009)
52. Levandowski RA. Regulatory perspective in the United States on cell cultures for production of inactivated influenza virus vaccines. Dev. Biol. Stand. 98, 171-175(1999)
53. Minor PD, Engelhardt OG, Wood JM, et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 27(22), 2907-2913 (2009)
54. Stacey GN, Phillips P. Quality assurance for cell substrates. Dev. Biol. Stand. 98, 141-151 (1999)
55. Steel J, Lowen AC, Pena L, et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol. 83(4), 1742-1753 (2009)
56. Wressnigg N, Voss D, Wolff T, et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine 27(21), 2851-2857 (2009)
57. Audsley JM. Tannock GA. The growth of attenuated vaccine donor strains in continuous cell lines. J. Virol. Methods 123(2) 187-193 (2005) (Pubitemid 40037796)
58. Romanova J, Katinger D, Ferko B, et al. Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res. 103, 187-193 (2004) (Pubitemid 38649078)
59. GhendonYZ, Markushin SG, Akopova II, et al. Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine Vaccine 23(38) 4678-4684 (2005) (Pubitemid 41132817)
60. Atmar RL. Emerging trends: vaccines in late development. Int. J. Infect. Dis. 14, e13 (2010)
61. Edwards KM, Sabow A, Pasternak A, Boslego JW. Strategies for broad global access to pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 471-493 (2009)
62. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum. Vaccin. 5(3), 126-135 (2009)
63. Perdue ML, Bright R. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Vaccine 29(Suppl. 1), A48-A50 (2011)
64. Chu C, Lugovtsev V, Golding H, Betenbaugh M, Shiloach J. Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc. Natl Acad. Sci USA 106(35), 14802-14807 (2009)
65. Genzel Y, Olmer RM, Schäfer B, Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 24, (35-36), 6074-6087 (2006) (Pubitemid 44175621)
66. Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 28(22), 3848-3855 (2010)
67. Murakami S, Horimoto T, Mai le Q, et al. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J. Virol. 82(21), 10502-10509 (2008) (Pubitemid 352691163)
68. Schwarzer J, Rapp E, Hennig R, et al. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine 27(32), 4325-4336 (2009)
69. Smith KA, Colvin CJ, Weber PS, Spatz SJ, Coussens PM. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine 26, 3778-3782 (2008)
70. United States Government Accountability Office. Influenza Pandemic: Sustaining Focus on the Nation's Planning and Preparedness. Report No.: GAO-09-334. Government Accountability Office, Washington DC, USA (2009)
71. Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Ther. 12(1), 21-30 (2010)
72. Crowe BA, Brühl P, Gerencer M, et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 29(2), 166-173 (2010)
73. Doroshenko A, Halperin SA. Trivalent MDCK cell culture derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 8, 679-688 (2009)
74. Ehrlich HJ, Müller M, Oh HM et al.; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358, 2573-2584 (2008) (Pubitemid 351831358)
75. Ehrlich HJ, Müller M, Fritsch S, et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200(7), 1113-1118 (2009)
76. Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem. 389(5), 569-577 (2008) (Pubitemid 351874194)
77. Kistner O, Howard MK, Spruth M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25(32), 6028-6036 (2007) (Pubitemid 47077543)
78. Liu J, Mani S, Schwartz R, Richman L, Tabor DE. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 28(5), 1285-1293 (2010)
79. Guan Y, Smith GJ, Webby R, Webster RG. Molecular epidemiology of H5N1 avian influenza. Rev. Sci. Tech. 28(1), 39-47 (2009)
80. Keitel W, Groth N, Lattanzi M, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a Phase 1/2 clinical trial. Vaccine 28(3), 840-848 (2010)
81. Keitel WA, Dekker CL, Mink C, et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 27(47), 6642-6648 (2009)
82. Partridge J, Kieny MP; World Health Organization H1N1 influenza vaccine Task Force. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 28(30), 4709-4712 (2010)
83. Neuzil KM, Bright RA. Influenza vaccine manufacture: keeping up with change. J. Infect. Dis. 200(6), 835-837 (2009)
84. Henkle E, Steinhoff MC, Omer SB, et al. Incidence of influenza virus infection in early infancy: a prospective study in south Asia. Pediatr. Infect. Dis. J. 30(2), 170-173 (2010)
85. Brooks WA, Goswami D, Rahman M, et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr. Infect. Dis. J. 29(3), 216-221 (2010)
86. Meena, G, Farooq M, Dang, et al. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol. Bioeng. 106(6), 906-917 (2010)
87. Farmvita www.farmavita.net/content/view/1493/84
88. The Pandemic and All Hazards Preparedness Act www.phe.gov/Preparedness/ legal/pahpa/Pages/default.aspx
89. Enders JF, Robbins FC, Weller TH. The cultivation of the poliomyelitis viruses in tissue culture. Nobel lecture. 11 December 1954 http://nobelprize. org/nobel-prizes/medicine/laureates/1954/enders-robbins-weller-lecture.pdf
90. Guidance for industry: characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatory Information/Guidances/ Vaccines/UCM202439.pdf
91. Cell lines used in influenza vaccine manufacturing offer significant advantages for the isolation and selection of viruses to update vaccine antigen composition www.controlinfluenza.com/summary
92. US Homeland Security Council. National strategy for pandemic influenza http://permanent.access.gpo.gov/lps64971/nspi.pdf
93. US Department of Health and Human Services. HHS pandemic influenza plan. www.hhs.gov/pandemicflu/plan/pdf/HHSPandemicInfluenzaPlan.pdf
94. US Department of Health and Human Services. HHS pandemic planning update, a report from Secretary Michael O. Leavitt www.flu.gov/professional/pdf/ panflu20060313.pdf
95. Federal business opportunities www.fbo.gov
96. Biomedical Advanced Research and Development Authority www.medicalcountermeasures.gov/BARDA/BARDA.aspx
97. US spending www.usaspending.gov
98. Herper M. "The Flu Vaccine Accelerator, " Forbes, May 25, 2009 www.forbes.com/2009/05/05/swine-flu-vaxinnate-business-healthcare-flu.html
99. Federal Business Opportunities Home www.fbo.gov
100. Serum Institute of India www.seruminstitute.com
101. Vaxiflu-S - India's first H1N1 vaccine is launched www.zyduscadila.com/ press/PressNote03-06-10.pdf